Teva secures FDA approval for Ajovy injection in migraine prevention
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in adults. The approval marks a pivotal advancement in migraine care, positioning Ajovy as the first anti-calcitonin gene-related peptide (CGRP) treatment approved in the United States with both quarterly (675 mg) […]